Skip to main content
Premium Trial:

Request an Annual Quote

DioGenix Raises $1.5M for Clinical Trial of MS Test

NEW YORK (GenomeWeb News) – Molecular diagnostics firm DioGenix today announced it has raised $1.5 million in a Series B financing round.

Existing investors including life sciences fund Nerveda participated in the round.

The financing will be used to support a prospective clinical trial to validate the firm's next-generation sequencing-based test for the early detection and diagnosis of multiple sclerosis. Called MSPrecise, the test measures DNA mutations found in rearranged immunoglobin genes in B cells isolated from cerebrospinal fluid. The mutations result when the adaptive immune system responds to a perceived challenge to a patient's central nervous system, and the changes "correspond to the production of diverse antibody libraries aimed at fighting the perceived foreign invader," DioGenix said.

It added that its method of measuring changes in immunity in the early stages of disease can also discern patients with more progressed disease that requires more aggressive treatment.

MSPrecise outperformed the specificity of the current standard of care for CSF analysis in patients suspected of having MS by almost two to one in a recently complete study, with no loss in sensitivity, the Gaithersburg, Md.-based firm said.

Last month DioGenix and Fast Forward announced a deal to develop a molecular diagnostic test for MS. As part of the agreement, Fast Forward provided funding to DioGenix for its ongoing clinical trial for MSPrecise.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.